Kala Pharmaceuticals Inc
$ 2.39
8.64%
02 Jun - close price
- Market Cap 40,708,000 USD
- Current Price $ 2.39
- High / Low $ 2.50 / 2.14
- Stock P/E N/A
- Book Value 0.58
- EPS -102.01
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.69 %
- ROE -2.39 %
- 52 Week High 1030.00
- 52 Week Low 2.10
About
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$1.50
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-15 | 2025-11-19 | 2025-08-08 | 2025-05-14 | 2025-03-31 | 2024-11-12 | 2024-08-06 | 2024-05-14 | 2024-03-29 | 2023-11-13 | 2023-08-04 | 2023-05-09 |
| Reported EPS | -0.1365 | -53.5 | -65.94 | -50.66 | -1.2316 | -96.5 | -122.27 | -4.19 | -79.07 | -150.12 | -174.05 | -6.99 |
| Estimated EPS | None | -50.5 | -102 | -127 | -2.47 | -135.5 | -229 | -2.89 | -200 | 23 | -214.5 | -4.52 |
| Surprise | 0 | -3 | 36.06 | 76.34 | 1.2384 | 39 | 106.73 | -1.3 | 120.93 | -173.12 | 40.45 | -2.47 |
| Surprise Percentage | None% | -5.9406% | 35.3529% | 60.1102% | 50.1377% | 28.7823% | 46.607% | -44.9827% | 60.465% | -752.6957% | 18.8578% | -54.646% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KALA
2026-05-20 08:42:38
This extensive report on KALA BIO (DB:27F) from Simply Wall St provides a detailed stock analysis, company overview, financial health, and a comprehensive timeline of recent news and announcements. It highlights the company's transition from a clinical-stage biotech to a dual-engine growth company with an AI platform, Researgency.ai, alongside its drug pipeline. The report also addresses significant risks including shareholder dilution, volatile stock performance, and Nasdaq compliance issues, while detailing the commercial deployment of its Bionic Intelligence Research Agent (BIRA) and future AI developments.
2026-05-17 09:39:51
This article provides an analysis of KALA BIO, Inc.'s management and leadership team, including recent management updates and perceived risks. It details executive appointments, resignations, annual general meetings, and critical business developments such as financing rounds, clinical trial results, and product launches. The company has transitioned from a clinical-stage biotech to a "dual-engine growth company" integrating a drug pipeline with an AI platform, Researgency.ai, while also facing challenges like share price volatility and Nasdaq compliance issues.
2026-05-16 07:39:21
This article provides a leadership and management team analysis for KALA BIO, Inc. (27F), highlighting recent executive changes, management tenure, and an overview of the company's board. It details numerous announcements regarding leadership appointments, resignations, financial offerings, clinical trial results, and Nasdaq compliance issues, alongside the company's strategic shift towards an AI platform in the biotech sector. The information covers the company's financial status, identified risks, and analyst coverage.
2026-05-15 19:10:16
KALA BIO (27F) shows a strong balance sheet with $10.8M in equity and no debt, but faces significant challenges including volatile share price, shareholder dilution, and unprofitability. The company recently launched its Bionic Intelligence Research Agent (BIRA) for the biotech and pharmaceutical sectors, aiming for dual-engine growth alongside its drug pipeline. However, KALA BIO has been grappling with delisting notices from Nasdaq due to minimum bid price and market value non-compliance.
2026-05-15 07:09:51
This article provides an analysis of KALA BIO, Inc.'s leadership and management team, including key executive details and recent management changes. It also details the company's financial status, ongoing clinical trials for KPI-012, and a significant strategic shift towards becoming a dual-engine growth company with a focus on an AI platform for the biotech industry, alongside its drug pipeline. The report highlights both financial offerings and risks such as share price volatility and dilution.
2026-05-14 18:09:29
KALA BIO, Inc. (DB:27F) is a clinical-stage biopharmaceutical company focusing on treatments for eye diseases, recently expanding into AI solutions for the biotech sector with its Researgency.ai platform. The company faces significant financial risks, including share dilution, volatility, and Nasdaq non-compliance warnings for minimum bid price and market value. Despite these challenges and the failure of its KPI-012 clinical trial, KALA BIO is pivoting towards a "dual-engine growth" model, combining its drug pipeline with AI-driven recurring revenue opportunities.
